← All trials
NCT04965597
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2021
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2026
- First posted
- Jul 16, 2021
- Last posted
- Nov 30, 2021
- Enrollment
- 40
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of WashingtonLead sponsor
- National Cancer Institute (NCI)Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- National Marrow Donor ProgramCollaborator
- University of WashingtonStudy chair
- University of MinnesotaStudy chair
- Blood and Marrow Transplant Clinical Trials NetworkCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.